Biomarkers in ALlergic diseases and allergen Immunotherapy - BALI

Franciscus Ziekenhuis0 个研究点目标入组 160 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•1. Positive Skin Prick Test (SPT) response of >= 8 mm wheal diameter and/or serum allergen-specific IgE levels higher than 0.70 kU/L to grass pollen, tree pollen and/or house dust mite (HDM) extract.
•2. Minimum of 18 years of age and a confirmed clinical diagnosis of allergic rhinitis.
•3. Clinical indication for AIT.
•4. Signed and dated informed consent (IC) form by a legally competent participant.

•1. History of chronic autoimmune disease (aside from asthma, atopic dermatitis or allergic rhinitis) which may interfere with results.
•2. Use of an antihistamines or decongestant therapy 7 days prior to screening visit.
•3. Prior exposure to any monoclonal antibody treatment within the past 12 months.
•4. Contraindication to sublingual or subcutaneous AIT.
•5. Current immunosuppressive treatment.
•6. Current pregnancy or breastfeeding, active pregnancy wish.
•7. Previous immunotherapy with grass pollen, tree pollen or house dust mite extract.

发起方

Franciscus Ziekenhuis